Nantes, France – November 21, 2022, 6:00 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces the publication in the peer-reviewed journal Science Advances of data from a first-in- class with CLEC-1, a novel myeloid immune checkpoint target in cancer immunotherapy.
The academic collaboration carried out with the team of Dr Elise Chiffoleau at the Nantes Transplantation and Immunology Research Center (1) has made it possible to identify CLEC-1 as a checkpoint.
CLEC-1 is a receptor expressed by myeloid cells inhibiting key pro-phagocytic and cross-activating functions of T cells, thereby limiting the antitumor immune response.
The article, titled “CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy” (2), reports fundamental findings and preclinical results showing that CLEC-1 is a new myeloid checkpoint that interacts with a newly identified ligand, TRIM-21, and confirming the therapeutic potential of CLEC-1 antagonist antibodies as an innovative cancer immunotherapy.